Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial looked at a medicine called AIN457 (also known as secukinumab) given by injection under the skin, compared to a dummy injection (placebo), in people with certain types of eye inflammation affecting the middle or back of the eye. A total of 125 people took part across four groups: 29 received AIN457 300 mg every two weeks, 31 received AIN457 300 mg every four weeks, 31 received AIN457 150 mg every four weeks, and 34 received the placebo every two weeks. The main thing the trial was measuring was how long it took before eye inflammation came back after the start of the study. The reported data shows that for the main measure — time until eye inflammation returned — a specific number of days was only reported for one of the four groups: the group receiving AIN457 150 mg every four weeks, where the figure was 178 days. For the other three groups, including the placebo group, this figure was not reported in the submitted data. For the secondary measures, all four groups showed a reduction in the score used to measure how much other immune-suppressing medication participants were taking (a lower score is described as a better outcome): the two-weekly 300 mg group reduced by 2.55 points, the four-weekly 300 mg group by 2.81 points, the four-weekly 150 mg group by 2.92 points, and the placebo group by 2.13 points. When it came to the cloudiness inside the eye (called vitreous haze, scored on a scale of 0 to 4), the reported average change from the start of the study to 24 weeks was very small across all groups: 0.02 for each of the three AIN457 groups and 0.2 for the placebo group. Vision, measured by a standard letter-reading test, showed small average improvements across all groups, ranging from 1.4 letters in the placebo group to 2.9 letters in the two-weekly 300 mg group. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 23290985) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Uveitis Trial, Terminated
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have a calm (non-active) form of chronic, non-infectious eye inflammation affecting the middle, back, or whole eye, with minimal signs of inflammation in both eyes for at least 6 weeks before the screening visit.
- You have needed certain medications to control or prevent your eye inflammation in the past 3 months, such as: daily steroid tablets (prednisone or similar) at a certain dose; steroid injections into or around the eye within the past 6 months; or certain immune-suppressing medications (such as cyclosporine, methotrexate, or mycophenolate), either alone or combined with steroids.
- If you cannot tolerate immune-suppressing medications, you may still be eligible, as decided by the trial doctor.
Who may not be able to join:
- You have been diagnosed with Behçet's disease, inflammation only at the front of the eye (anterior uveitis), or certain eye conditions where inflammation tends to go away on its own or does not show typical signs of inflammation (such as PIC or AZOOR).
- You currently have active eye inflammation in one or both eyes at the time of the screening visit.
- You need very high daily doses of steroid tablets (1 mg per kilogram of body weight or more) to keep your eye inflammation under control.
- You have received anti-VEGF injections into the study eye within the 3 months before screening (confirm with trial site).
- You have had a long-term steroid implant (Retisert®) placed in the study eye within the last 3 years, or a dexamethasone implant or other investigational steroid implant within the last 6 months.
- You have had eye surgery or laser treatment in the study eye within the 6 weeks before screening (a simple diagnostic fluid sample with a small needle may be acceptable — confirm with trial site).
- You have received any biologic therapy (such as infliximab, adalimumab, or similar medicines given by injection or drip) within the 3 months before screening, and no other biologic treatments will be allowed during the trial.
- You have been treated with strong chemotherapy-type immune-suppressing drugs (such as cyclophosphamide or chlorambucil) within the past 5 years.
- You have received any live vaccines (such as chickenpox or measles vaccines) within 2 months before screening, and no live vaccines will be allowed during the trial.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Time to First Recurrence in Any Eye of Active Intermediate, Posterior, or Panuveitis From Baseline
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.